APA (7th ed.) Citation

Hafez, A. E., Abdelazeem, A. H., Abdelhakeem, M. A., & Darwesh, A. F. (2022). Clinical utility of anti-carbamylated antibody in rheumatoid arthritis female patients: Emerging predictive value compared to anti-cyclic citrullinated peptide and rheumatoid factor. Elsevier.

Chicago Style (17th ed.) Citation

Hafez, Ahmed E., Aya H. Abdelazeem, Mohamed A. Abdelhakeem, and Ayman F. Darwesh. Clinical Utility of Anti-carbamylated Antibody in Rheumatoid Arthritis Female Patients: Emerging Predictive Value Compared to Anti-cyclic Citrullinated Peptide and Rheumatoid Factor. Elsevier, 2022.

MLA (8th ed.) Citation

Hafez, Ahmed E., et al. Clinical Utility of Anti-carbamylated Antibody in Rheumatoid Arthritis Female Patients: Emerging Predictive Value Compared to Anti-cyclic Citrullinated Peptide and Rheumatoid Factor. Elsevier, 2022.